To define the basis of the heterogeneity of angiotensinogen, we have characterized (a) the immunoreactivity of high molecular weight (HMW) and low molecular weight (LMW) plasma angiotensinogen, (b) the angiotensinogen precursor synthesized by cell-free translation, and (c) angiotensinogen secreted by human hepatoma (Hep G2)